Deerfield Management Company, L.P. (Series C) Nuvalent, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.04 Billion
- Q4 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Nuvalent, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 17,991,024 shares of NUVL stock, worth $1.38 Billion. This represents 34.87% of its overall portfolio holdings.
Number of Shares
17,991,024
Previous 19,991,024
10.0%
Holding current value
$1.38 Billion
Previous $2.05 Billion
31.14%
% of portfolio
34.87%
Previous 38.02%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
233Shares Held
57.8MCall Options Held
834KPut Options Held
490K-
Paradigm Biocapital Advisors LP New York, NY5.36MShares$412 Million16.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$345 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$232 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.62MShares$201 Million6.84% of portfolio
-
Commodore Capital LP New York, NY1.62MShares$124 Million12.71% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.3B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...